Keith T Flaherty1, Michael Hennig2, Sandra J Lee3, Paolo A Ascierto4, Reinhard Dummer5, Alexander M M Eggermont6, Axel Hauschild7, Richard Kefford8, John M Kirkwood9, Georgina V Long10, Paul Lorigan11, Andreas Mackensen12, Grant McArthur13, Steven O'Day14, Poulam M Patel15, Caroline Robert16, Dirk Schadendorf17. 1. Center for Melanoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA. 2. Biostatistics and Epidemiology, GlaxoSmithKline, Munich, Germany. 3. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. 4. Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy-Istituto Nazionale Tumori Fondazione "G Pascale", Napoli, Italy. 5. Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. 6. Gustave Roussy Cancer Campus, Paris-Sud University Grand Paris, Villejuif, France. 7. Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, University Hospital Kiel, Kiel, Germany. 8. Westmead Hospital and Melanoma Institute Australia, University of Sydney, NSW, Australia. 9. Skin Cancer Program University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. 10. Melanoma Institute Australia and the University of Sydney, Sydney, NSW, Australia. 11. Institute of Cancer Sciences, Faculty of Medical & Human Sciences, University of Manchester, Manchester, UK. 12. Department of Internal Medicine 5-Hematology/Oncology, University of Erlangen, Erlangen, Germany. 13. Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne, VIC, Australia. 14. Beverly Hills Cancer Center, Beverly Hills, CA, USA. 15. Academic Unit of Oncology, University of Nottingham, Nottingham, UK. 16. Dermatology and INSERM Unit 981 Gustave Roussy Cancer Campus and Paris-Sud University Grand Paris, Villejuif, France. 17. Department of Dermatology, University Hospital Essen, Essen, Germany. Electronic address: dirk.schadendorf@uk-essen.de.
Abstract
BACKGROUND: Recent phase 3 trials have shown an overall survival benefit in metastatic melanoma. We aimed to assess whether progression-free survival (PFS) could be regarded as a reliable surrogate for overall survival through a meta-analysis of randomised trials. METHODS: We systematically reviewed randomised trials comparing treatment regimens in metastatic melanoma that included dacarbazine as the control arm, and which reported both PFS and overall survival with a standard hazard ratio (HR). We correlated HRs for overall survival and PFS, weighted by sample size or by precision of the HR estimate, assuming fixed and random effects. We did sensitivity analyses according to presence of crossover, trial size, and dacarbazine dose. FINDINGS: After screening 1649 reports and meeting abstracts published before Sept 8, 2013, we identified 12 eligible randomised trials that enrolled 4416 patients with metastatic melanoma. Irrespective of weighting strategy, we noted a strong correlation between the treatment effects for PFS and overall survival, which seemed independent of treatment type. Pearson correlation coefficients were 0·71 (95% CI 0·29-0·90) with a random-effects assumption, 0·85 (0·59-0·95) with a fixed-effects assumption, and 0·89 (0·68-0·97) with sample-size weighting. For nine trials without crossover, the correlation coefficient was 0·96 (0·81-0·99), which decreased to 0·93 (0·74-0·98) when two additional trials with less than 50% crossover were included. Inclusion of mature follow-up data after at least 50% crossover (in vemurafenib and dabrafenib phase 3 trials) weakened the PFS to overall survival correlation (0·55, 0·03-0·84). Inclusion of trials with no or little crossover with the random-effects assumption yielded a conservative statement of the PFS to overall survival correlation of 0·85 (0·51-0·96). INTERPRETATION: PFS can be regarded as a robust surrogate for overall survival in dacarbazine-controlled randomised trials of metastatic melanoma; we postulate that this association will hold as treatment standards evolve and are adopted as the control arm in future trials. FUNDING: None.
BACKGROUND: Recent phase 3 trials have shown an overall survival benefit in metastatic melanoma. We aimed to assess whether progression-free survival (PFS) could be regarded as a reliable surrogate for overall survival through a meta-analysis of randomised trials. METHODS: We systematically reviewed randomised trials comparing treatment regimens in metastatic melanoma that included dacarbazine as the control arm, and which reported both PFS and overall survival with a standard hazard ratio (HR). We correlated HRs for overall survival and PFS, weighted by sample size or by precision of the HR estimate, assuming fixed and random effects. We did sensitivity analyses according to presence of crossover, trial size, and dacarbazine dose. FINDINGS: After screening 1649 reports and meeting abstracts published before Sept 8, 2013, we identified 12 eligible randomised trials that enrolled 4416 patients with metastatic melanoma. Irrespective of weighting strategy, we noted a strong correlation between the treatment effects for PFS and overall survival, which seemed independent of treatment type. Pearson correlation coefficients were 0·71 (95% CI 0·29-0·90) with a random-effects assumption, 0·85 (0·59-0·95) with a fixed-effects assumption, and 0·89 (0·68-0·97) with sample-size weighting. For nine trials without crossover, the correlation coefficient was 0·96 (0·81-0·99), which decreased to 0·93 (0·74-0·98) when two additional trials with less than 50% crossover were included. Inclusion of mature follow-up data after at least 50% crossover (in vemurafenib and dabrafenib phase 3 trials) weakened the PFS to overall survival correlation (0·55, 0·03-0·84). Inclusion of trials with no or little crossover with the random-effects assumption yielded a conservative statement of the PFS to overall survival correlation of 0·85 (0·51-0·96). INTERPRETATION: PFS can be regarded as a robust surrogate for overall survival in dacarbazine-controlled randomised trials of metastatic melanoma; we postulate that this association will hold as treatment standards evolve and are adopted as the control arm in future trials. FUNDING: None.
Authors: Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Ulrich Keilholz; Cornelis J A Punt; Martin Gore; Wim Kruit; Poulam Patel; Danielle Lienard; Jose Thomas; Thomas M Proebstle; Alexander Schmittel; Dirk Schadendorf; Thierry Velu; Sylvie Negrier; Ulrich Kleeberg; Frederic Lehman; Stefan Suciu; Alexander M M Eggermont Journal: J Clin Oncol Date: 2005-09-20 Impact factor: 44.544
Authors: Poulam M Patel; Stefan Suciu; Laurent Mortier; Wim H Kruit; Caroline Robert; Dirk Schadendorf; Uwe Trefzer; Cornelis J A Punt; Reinhard Dummer; Neville Davidson; Juergen Becker; Robert Conry; John A Thompson; Wen-Jen Hwu; Kristel Engelen; Sanjiv S Agarwala; Ulrich Keilholz; Alexander M M Eggermont; Alain Spatz Journal: Eur J Cancer Date: 2011-05-18 Impact factor: 9.162
Authors: Agop Y Bedikian; Michael Millward; Hubert Pehamberger; Robert Conry; Martin Gore; Uwe Trefzer; Anna C Pavlick; Ronald DeConti; Evan M Hersh; Peter Hersey; John M Kirkwood; Frank G Haluska Journal: J Clin Oncol Date: 2006-09-11 Impact factor: 44.544
Authors: Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245
Authors: Caroline Robert; Reinhard Dummer; Ralf Gutzmer; Paul Lorigan; Kevin B Kim; Marta Nyakas; Ana Arance; Gabriella Liszkay; Dirk Schadendorf; Mireille Cantarini; Stuart Spencer; Mark R Middleton Journal: Lancet Oncol Date: 2013-06-02 Impact factor: 41.316
Authors: S O'Day; A Pavlick; C Loquai; D Lawson; R Gutzmer; J Richards; D Schadendorf; J A Thompson; R Gonzalez; U Trefzer; P Mohr; C Ottensmeier; D Chao; B Zhong; C J de Boer; C Uhlar; D Marshall; M E Gore; Z Lang; W Hait; P Ho Journal: Br J Cancer Date: 2011-07-12 Impact factor: 7.640
Authors: Denis L Jardim; Denis L Fontes Jardim; Maria Schwaederle; Caimiao Wei; J Jack Lee; David S Hong; Alexander M Eggermont; Richard L Schilsky; John Mendelsohn; Vladimir Lazar; Razelle Kurzrock Journal: J Natl Cancer Inst Date: 2015-09-15 Impact factor: 13.506
Authors: Jason J Luke; Pierre L Triozzi; Kyle C McKenna; Erwin G Van Meir; Jeffrey E Gershenwald; Boris C Bastian; J Silvio Gutkind; Anne M Bowcock; Howard Z Streicher; Poulam M Patel; Takami Sato; Jeffery A Sossman; Mario Sznol; Jack Welch; Magdalena Thurin; Sara Selig; Keith T Flaherty; Richard D Carvajal Journal: Pigment Cell Melanoma Res Date: 2014-09-01 Impact factor: 4.693
Authors: Howard L Kaufman; Lawrence H Schwartz; William N William; Mario Sznol; Kyle Fahrbach; Yingxin Xu; Eric Masson; Andrea Vergara-Silva Journal: J Cancer Res Clin Oncol Date: 2018-08-21 Impact factor: 4.553
Authors: Joanna Mangana; Phil F Cheng; Katja Schindler; Benjamin Weide; Ulrike Held; Anna L Frauchiger; Emanuella Romano; Katharina C Kähler; Sima Rozati; Markus Rechsteiner; Holger Moch; Olivier Michielin; Claus Garbe; Axel Hauschild; Christoph Hoeller; Reinhard Dummer; Simone M Goldinger Journal: PLoS One Date: 2015-10-01 Impact factor: 3.240